What is Lisata Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lisata Therapeutics's interest expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lisata Therapeutics's Operating Income for the
three
months ended in Mar. 2024 was $ -6.60 Mil. Lisata Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Lisata Therapeutics has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Lisata Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lisata Therapeutics (NAS:LSTA) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Lisata Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-6.60 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $0.00 Mil.
Lisata Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| Lisata Therapeutics had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Lisata Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
Lisata Therapeutics (Lisata Therapeutics) Business Description
Traded in Other Exchanges
Address
110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.
Executives
| David W. Slack |
director, officer: President & CBO |
110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920 |
| Heidi Henson |
director |
2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008 |
| Mohammad Azab |
director |
C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568 |
| Erkki Ruoslahti |
director |
P.O. BOX 544, BUELLTON CA 93427 |
| Steven S Myers |
director |
4695 MACAUTHUR COURT, EIGHTH FLOOR, NEWPORT BEACH CA 92660 |
| Kristen K Buck |
officer: EVP, R&D and CMO |
110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920 |
| Todd C Girolamo |
officer: CLO, SVP of Corp Dev |
110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920 |
| Anne Clem Whitaker |
director |
109 BRIERY BRANCH COURT, MORRISVILLE NC 27560 |
| Michael H. Davidson |
director |
OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540 |
| Cynthia Schwalm |
director |
C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709 |
| David J Mazzo |
director, officer: Chief Executive Officer |
110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920 |
| Joseph Talamo |
officer: SVP and CFO |
CALADRIUS BIOSCIENCES, INC., 800 WESTCHESTER AVENUE. STE N341, RYE BROOK NY 10573 |
| Douglas W Losordo |
officer: See Remarks |
13 FOX MEADOW RD, SCARSDALE NY 10583 |
| Anford |
10 percent owner |
P.O. BOX 5039, SIOUX FALLS SD 57117 |
| Health Sanford |
10 percent owner |
P.O. BOX 5039, SIOUX FALLS SD 57117 |
Lisata Therapeutics (Lisata Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSTA has been successfully added to your 